Caxton Associates (New York)’s Medtronic MDT Stock Holding History

Caxton Associates (New York)’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,774	Closed	-$3.17M	–	580
2022 Q4	$3.17M	Buy	40,774 +31,824	+356%	+$2.58M	0.21%	30
2022 Q3	$723K	Sell	8,950 -11,115	-55%	-$999K	0.1%	174
2022 Q2	$1.8M	Buy	+20,065	New	+$2.03M	0.18%	43
2019 Q2	–	Sell	-10,809	Closed	-$984K	–	475
2019 Q1	$984K	Buy	+10,809	New	+$967K	0.14%	77
2018 Q2	–	Sell	-13,692	Closed	-$1.1M	–	438
2018 Q1	$1.1M	Sell	13,692 -3,085	-18%	-$254K	0.06%	174
2017 Q4	$1.35M	Buy	16,777 +9,577	+133%	+$767K	0.07%	168
2017 Q3	$560K	Buy	7,200 +300	+4%	+$24.9K	0.02%	297
2017 Q2	$612K	Hold	6,900	–	–	0.02%	258
2017 Q1	$556K	Buy	+6,900	New	+$539K	﹤0.01%	225
2015 Q2	–	Sell	-30,000	Closed	-$2.34M	–	184
2015 Q1	$2.34M	Buy	+30,000	New	+$2.27M	0.1%	123

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Caxton Associates (New York)'s MDT Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Medtronic (MDT) in Q1 2023, closing a stake of 40,774 shares — an estimated $3.17M sold.

Caxton Associates (New York) first reported a position in MDT in Q1 2015 and held it in 10 quarters. The position peaked at $3.17M in Q4 2022. 1,990 funds tracked by Wall St. Rank hold MDT as of Q1 2023.

Caxton Associates (New York) reported no remaining Medtronic position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 40,774 Medtronic shares in Q1 2023, an estimated $3.17M.
Caxton Associates (New York) first reported a position in Medtronic in Q1 2015 and held it in 10 quarters.
Caxton Associates (New York)'s Medtronic position peaked at $3.17M in Q4 2022.
1,990 funds tracked by Wall St. Rank held Medtronic as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.